Genmab — November 2017
-
18,50 min inde Dara opsamling. https://www.youtube.com/watch?v=hjFJLDHh9j4
-
Herlig historie til sidst med damen der på 4. år er i CR med dara mono. Plesner fortalte i foråret en lignende historie med en patient, som efter 9(!) forudgående behandlinger kom i CR med dara mono. Desværre er det langt fra alle, der har så god effekt af dara.
-
I denne video (som har været vist før) taler han om, at de på verdensplan har identificeret 15 personer i RRMM, der ikke har spor af sygdommen efter dara mono. Kunne være interessant om de fandt ud af hvorfor, og om det kunne udnyttes til forbedring af behandlingen. https://www.youtube.com/watch?v=HnMOPPS9Gdk
-
God morgen og tak for link til jkj.

-
God morgen

-
Novartis said on Monday it submitted an application for its cell therapy Kymriah to be approved in Europe for children and young adults with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL) http://in.reuters.com/article/us-novartis-kymriah/novartis-seeks-european-approval-of-cell-therapy-kymriah-idINKBN1D60JY?feedType=RSS&feedName=health&utm_source=Twitter&utm_medium=Social&utm_campaign=Feed%3A+reuters%2FINhealth+(News+%2F+IN+%2F+Health)
-
not sure if you saw Dara abstract 3888, where the researchers said : Based on this work, we are planning to open a multi-institutional early phase clinical trial for children and young adults with relapsed and refractory T-ALL. https://ash.confex.com/ash/2017/webprogram/Paper101472.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Dejlig video for øvrigt.